Hristova Preslava Mihaylova, Nankov Vladislav Milkov, Hristov Ivaylo Georgiev, Trifonov Stefan Venelinov, Alexandrova Alexandra Sashova, Hitkova Hristina Yotova
Department of Microbiology and Virology, Faculty of Pharmacy, Medical University Pleven, 1 St. Kliment Ohridski Str., 5800, Pleven, Bulgaria.
Department of Anatomy, Histology, Cytology and Biology, Medical University Pleven, Pleven, Bulgaria.
Gut Pathog. 2023 Mar 9;15(1):12. doi: 10.1186/s13099-023-00538-z.
Vancomycin-resistant enterococci (VRE) are well known agents that colonize the gastrointestinal tract of immunocompromised patients, especially those with hematologic malignancies. The aim of the current study was to determine the incidence of and risk factors for colonization with VRE among patients with hematologic malignancies.
For a nine-month period, all patients admitted to the Hematology ward at University Hospital in Pleven, Bulgaria who had hematologic malignancy and duration of hospitalization of more than 48 h were screened for colonization with VRE. The data collected from patients and their medical records during the entire hospital stay included: demographic characteristics, clinical information and information about all antimicrobials used. A longitudinal study was used to assesses the risk factors and statistical analysis was performed using SPSS version 27.0.
A total of 119 patients were enrolled in the study. Colonization with VRE was established in 18 of them. One patient carried two species, resulting in a total of 19 VRE: 12 Enterococcus gallinarum, 4 Enterococcus casseliflavus, 2 Enterococcus faecium and 1 Enterococcus faecalis. VanA phenotype, with high-level resistance of vancomycin (MIC ≥ 256 μg/ml) and teicoplanin (MIC = 96 μg/ml), was demonstrated by one E. faecium, which carried vanA. The other E. faecium and E. faecalis expressed low-level resistance to vancomycin (MICs: 8 μg/ml and 12 μg/ml), susceptibility to teicoplanin (MICs = 0.5 μg/ml) and vanB was detected. All E. gallinarum and E. casseliflavus showed low-level resistance to vancomycin and susceptibility to teicoplanin. E. gallinarum strains were positive for vanC1 and E. casseliflavus for vanC2. Only two patients were colonized with vanA or vanB enterococci and the rest 16 were positive for vanC. The univariate analysis revealed that patient's age (70-79 years; p = 0.025) and multiple myeloma (p = 0.001) are risk factors for VRE acquisition among the investigated patients. In addition, the multivariate analysis confirmed that patient's age (70-79 years) is an independent risk factor for VRE colonization.
Our results showed that 15.1% of patients with hematologic malignancies were colonized with VRE. There was a distinct prevalence of vanC enterococci. Among the analyzed risk factors, advanced age and multiple myeloma contributed to VRE acquisition.
耐万古霉素肠球菌(VRE)是已知的可在免疫功能低下患者的胃肠道定植的病原体,尤其是血液系统恶性肿瘤患者。本研究的目的是确定血液系统恶性肿瘤患者中VRE定植的发生率和危险因素。
在九个月的时间里,对保加利亚普列文大学医院血液科收治的所有患有血液系统恶性肿瘤且住院时间超过48小时的患者进行了VRE定植筛查。在患者整个住院期间从患者及其病历中收集的数据包括:人口统计学特征、临床信息以及所有使用过的抗菌药物的信息。采用纵向研究来评估危险因素,并使用SPSS 27.0版进行统计分析。
共有119名患者纳入本研究。其中18名患者被确定为VRE定植。一名患者携带两种菌株,共检出19株VRE:12株鹑鸡肠球菌、4株格氏肠球菌、2株粪肠球菌和1株屎肠球菌。一株携带vanA的屎肠球菌表现出VanA表型,对万古霉素(MIC≥256μg/ml)和替考拉宁(MIC = 96μg/ml)具有高水平耐药性。另一株屎肠球菌和屎肠球菌对万古霉素表现出低水平耐药(MIC分别为8μg/ml和12μg/ml),对替考拉宁敏感(MIC = 0.5μg/ml),并检测到vanB。所有鹑鸡肠球菌和格氏肠球菌对万古霉素表现出低水平耐药,对替考拉宁敏感。鹑鸡肠球菌菌株vanC1呈阳性,格氏肠球菌vanC2呈阳性。只有两名患者被vanA或vanB肠球菌定植,其余16名患者vanC呈阳性。单因素分析显示,患者年龄(70 - 79岁;p = 0.025)和多发性骨髓瘤(p = 0.001)是所调查患者获得VRE的危险因素。此外,多因素分析证实患者年龄(70 - 79岁)是VRE定植的独立危险因素。
我们的结果显示,15.1%的血液系统恶性肿瘤患者被VRE定植。vanC肠球菌有明显的流行趋势。在分析的危险因素中,高龄和多发性骨髓瘤与获得VRE有关。